Anti-CD20 CART-transduced T cells - Cellular Biomedicine Group

Drug Profile

Anti-CD20 CART-transduced T cells - Cellular Biomedicine Group

Alternative Names: Anti-CD20 CART cells; Anti-CD20 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group; CAR-CD20 T cell therapy; CART20; CBM-C20.1; CBM-CD20 1; Genetically engineered lymphocyte therapy - Cellular Biomedicine Group

Latest Information Update: 25 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chinese PLA General Hospital
  • Developer Cellular Biomedicine Group; Chinese PLA General Hospital
  • Class CAR-T cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Leukaemia; Lymphoma

Most Recent Events

  • 24 Aug 2017 Phase-I/II development is ongoing in China (NCT01735604)
  • 06 Jun 2017 Pharmacodynamic results from a preclinical study in Lymphoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 09 Aug 2016 Cellular Biomedicine Group has patent protection for Anti-CD20 chimeric antigen receptor T cell therapy in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top